WallStreetZenWallStreetZen

NASDAQ: NGNE
Neurogene Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for NGNE

Based on 2 analysts offering 12 month price targets for Neurogene Inc.
Min Forecast
$31.00+3.47%
Avg Forecast
$43.00+43.52%
Max Forecast
$55.00+83.58%

Should I buy or sell NGNE stock?

Based on 2 analysts offering ratings for Neurogene Inc.
Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their NGNE stock forecasts and price targets.

NGNE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-03-19
lockedlocked$00.00+00.00%2024-01-05

1 of 1

Forecast return on equity

Is NGNE forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.83%

Forecast return on assets

Is NGNE forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

NGNE revenue forecast

What is NGNE's revenue in the next 1 years based on estimates from 1 analyst?
Avg 1 year Forecast
$28.7M

NGNE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NGNE$29.96$43.00+43.52%Strong Buy
MREO$2.74$6.50+137.23%Strong Buy
PEPG$11.93$20.00+67.64%Buy
BMEA$10.78$55.80+417.63%Buy
ITOS$10.80$33.33+208.64%Strong Buy
View Top Biotech Stocks

Neurogene Stock Forecast FAQ

Is Neurogene Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: NGNE) stock is to Strong Buy NGNE stock.

Out of 2 analysts, 1 (50%) are recommending NGNE as a Strong Buy, 1 (50%) are recommending NGNE as a Buy, 0 (0%) are recommending NGNE as a Hold, 0 (0%) are recommending NGNE as a Sell, and 0 (0%) are recommending NGNE as a Strong Sell.

If you're new to stock investing, here's how to buy Neurogene stock.

What is NGNE's revenue growth forecast for 2028-2028?

(NASDAQ: NGNE) Neurogene's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.94%.

Neurogene's revenue in 2024 is $0.

In 2028, NGNE is forecast to generate $368,919,228 in revenue, with the lowest revenue forecast at $368,919,228 and the highest revenue forecast at $368,919,228.

What is NGNE's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: NGNE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is NGNE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year NGNE price target, the average NGNE price target is $43.00, with the highest NGNE stock price forecast at $55.00 and the lowest NGNE stock price forecast at $31.00.

On average, Wall Street analysts predict that Neurogene's share price could reach $43.00 by Mar 19, 2025. The average Neurogene stock price prediction forecasts a potential upside of 43.52% from the current NGNE share price of $29.96.

What is NGNE's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: NGNE) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.